Physician profile
Hamza Hashmi
NPI 1164862652
$244,285.81
in general payments reported to CMS, 2019-2025
42 companies · $17K in 2025
The $17K reported for 2025 was more than what 82% of Hematology (Internal Medicine) providers received nationally (typical 2025 total: $1,177).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,581 · 2020: $538 · 2021: $11K · 2022: $71K · 2023: $123K · 2024: $17K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $59K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $48K · Travel and Lodging: $22K · Consulting Fee: $21K · Food and Beverage: $7,136 · Education: $89.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $59,495.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $47,508.25 |
| Travel and Lodging | $21,899.57 |
| Consulting Fee | $20,666.10 |
| Food and Beverage | $7,135.54 |
| Education | $89.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $81,529.29 | 2022-2025 | Xpovio |
| Janssen Biotech, INC. | $54,350.40 | 2019-2025 | Tecvayli, Carvykti, Darzalex |
| Glaxosmithkline, LLC. | $50,069.33 | 2020-2022 | |
| Amgen INC. | $15,506.42 | 2019-2024 | Kyprolis |
| Pfizer INC. | $9,345.83 | 2023 | |
| Sanofi-Aventis U.S. LLC | $6,863.72 | 2021-2022 | |
| Legend Biotech USA INC. | $6,485.28 | 2024-2025 | Carvykti |
| Genzyme Corporation | $4,503.25 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $3,042.42 | 2019-2022 | |
| Celgene Corporation | $2,258.47 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $2,130.26 | 2022-2025 | Darzalex, Talvey, Carvykti |
| Janssen Global Services, LLC | $1,698.80 | 2021-2024 | Talvey, Tecvayli, Carvykti |
| Secura Bio, INC. | $1,146.95 | 2021-2025 | Copiktra |
| Incyte Corporation | $566.82 | 2019-2023 | Jakafi |
| Eusa Pharma (US) LLC | $422.71 | 2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamza Hashmi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.